Wyeth

American Home Products Corporation

Magda Asselin

Derek Cecil Cole

Deborah Ann Evrard

Richard Eric Mewshaw

Adam Matthew Gilbert

Kristin L Meagher

Gary Paul Stack

Ping Zhou

Dahui Zhou

George Theodore Grosu

Joseph Raymond Stock

Gerardo De Francisco

Albert Jean Robichaud

Allan Wissner

Aranapakam Mudumbai Venkatesan

Wayne Everett Childers

Diane H Boschelli

Russell Dushin

John W Ellingboe

Annmarie Louise Sabb

Jonathan Laird Gross

Lawrence Nathan Tumey

Ji-In Kim

William Ronald Solvibile

Osvaldo Dos Santos

Biqi Wu

Michael Byron Webb

Lisa Marie Havran

Yanong Daniel Wang

Amarnauth Shastrie Prashad

Zhen-jia Chen

Diane Marie Joseph-McCarthy

Zhongqi Shen

Chuan S Niu

James Jacob Bicksler

Michael Bryon Webb

Joan Chen

Dan Chaekoo Chong

Jin-In Kim

Diane Harris Boschelli

Diane Marie Joseph-Mccarthy

Diane Marie Joseph-Mcarthy

The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor. 

N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists

N-substituted-azacyclylamines as histamine-3 antagonists

The present teachings provide compounds of formula I and their pharmaceutically acceptable salts, hydrates, and esters, wherein R, R, and X are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating autoimmune and inflammatory diseases by administering a therapeutically effective amount of a compound or compounds of formula I to a mammal including a human.

Substituted 3-cyanopyridines as protein kinase inhibitors

The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a CNS disorder related to or affected by the 5-HT6 receptor. 

Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands

The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction. The invention relates to compounds and pharmaceutically acceptable salts of formula (I'): wherein R-R, R, R, and n are set forth in the specification. The invention also relates to pharmaceutical compositions comprising compounds and pharmaceutically acceptable salts of formula (I&#x2032;).

[object Object]

Compounds of the Formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

Antidepressant piperidine derivatives of heterocyclefused benzodioxans

The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a CNS disorder related to or affected by the 5-HT6 receptor 

Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands

Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such compounds are disclosed. Methods of using benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives and compositions containing such composition in the treatment and/or prevention of serotonin-related disorders, such as depression and anxiety, are also disclosed. In addition, processes for the preparation of benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives are disclosed. Benzofuranyl- and benzothienyl-piperzinyl quinoline derivatives of Formula I are disclosed: 

Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use

Compounds of the Formula:are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

Antidepressant piperidine derivatives of heterocycle-fused benzodioxans

Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression

Compounds are provided which are useful for the treatment of serotonin-affected neurological disorders which comprise

This invention provides novel compounds and pharmaceutical compositions and methods of using the compounds in the treatment of central nervous system disorders, such as anxiety and depression, the compounds having the formula I:

&lsqb;(Indol-3-yl)-cycloalkyl&rsqb;-3-substituted azetidines for the treatment of central nervous system disorders

Method of treating bone loss by stimulation of calcitonin

A compound of formula (I) ##STR1## wherein: X=N and Y=CH or X=CH and Y=N

Pyrazolopyrimidine-2,4-dione sulfonamides

Growing community of inventors

Mahwah, NJ, United States of America

Magda Asselin